FDA ACCEPTS NEW DRUG APPLICATION FOR CELECOR'S INVESTIGATIONAL HEART-ATTACK DRUG

Read post on prnewswire.com

Agency assigns zalunfiban (DisaggproTM) a PDUFA target action date of June 18, 2027 DEL MAR, Calif., Sept. 30, 2026 /PRNewswire/ -- The U.S. Food and Drug Administration has accepted CeleCor Therapeutics' New Drug Application (NDA) for zalunfiban (DisaggproTM) and assigned a target action...